License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	$ 72,666,000	$ 45,930,000
License, Collaboration and Other Revenue
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	49,555,000	45,930,000
License, Collaboration and Other Revenue | Mitsubishi Tanabe Pharma Corporation
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	0	9,092,000
License, Collaboration and Other Revenue | Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	26,223,000	19,599,000
License, Collaboration and Other Revenue | Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	21,956,000	16,974,000
License, Collaboration and Other Revenue | Mitsubishi Tanabe Pharma Corporation and Otsuka Pharmaceutical Company Limited
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	48,179,000	45,665,000
License, Collaboration and Other Revenue | Japan Tobacco Incorporation and Torii Pharmaceutical Company Limited
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	1,228,000
License, Collaboration and Other Revenue | Clinical and Regulatory Activities
License, Collaboration and Other Revenue:
License, Collaboration and Other Revenue	$ 148,000	$ 265,000